Send to

Choose Destination
Am J Respir Crit Care Med. 2011 Sep 1;184(5):561-8. doi: 10.1164/rccm.201012-2090OC.

Randomized, placebo-controlled clinical trial of an aerosolized β₂-agonist for treatment of acute lung injury.

Collaborators (188)

Hudson L, Hough C, Neff M, Sims K, Watkins T, Steingrub J, Tidswell M, DeSouza L, Kardos C, Kozikowski L, Kozikowski K, Guntupalli K, Bandi V, Pope C, Brower R, Fessler H, Hager D, Mendez-Tellez P, Oakjones K, Needham D, Sevransky J, Workneh A, Han S, Murray S, Shanholtz C, Netzer G, Rock P, Sampaio A, Titus J, Harrington T, Herr D, Lee B, Bolouri N, Wiedemann H, Ashton R, Culver D, Frederick T, Komara J, Guzman J, Reddy A, Hejal R, Andrews M, Haney D, Connors A, Lasalvia S, Thornton J, Warren E, Moss M, Benson A, Burnham E, Clark B, Gray L, Higgins C, Maloney B, Mealer M, Frankel S, Bost T, Dennen P, Hodgin K, Douglas I, Overdier K, Thompson K, Wolken R, MacIntyre N, Brown L, Cox C, Gentile M, Govert J, Knudsen N, Carson S, Chang L, Lanier J, Wheeler A, Bernard G, Hays M, Mogan S, Rice T, Hite R, Morris P, Howard A, Harvey A, Bender K, Wright P, Gross S, McLean J, Overton A, Truwit J, Enfield K, Marshall M, Clemmer T, Weaver L, Zenger M, Krueger J, Morris A, Ahmed A, Austin A, Dean N, Grissom C, Hirshberg E, Kumar N, Miller R, Napoli L, Orme J, Pandita S, Schreiber G, Struck L, Thomas F, Thomsen G, Lawton C, Leung F, Kim P, Fujii T, Baughman J, Kerwin B, Hanselman D, Sundar K, Alward W, Hill T, Campbell E, Ludwig K, Nielsen D, Pearce M, Matthay M, Calfee C, Daniel B, Eisner M, Garcia O, Johnson E, Kallet R, Kordesch K, Liu K, Zhou H, Peterson M, Blaauw J, Albertson T, Vlastelin E, Hubmayr R, Brown D, Gajic O, Hinds R, Holets S, Kor D, Passe M, deBoisblanc B, Lauto P, Romaine C, Meyaski G, Hunt J, Marr A, Long EK, Brierre S, LeBlanc C, Taylor D, Jain S, Seoane L, Simeone F, Fearon J, Duchesne J, Schoenfeld D, Aquino M, Dorer D, Guha M, Hammond E, Lavery N, Lazar P, Molina I, Morse R, Oldmixon C, Rawal B, Ringwood N, Shui A, Smoot E, Thompson B, Harabin A, Bredow S, Waclawiw M, Weinmann G, Spragg R, Slutsky A, Levy M, Markovitz B, Petkova E, Weijer C, Sznajder J, Begg M, Israel E, Lewis J, Parsons P.



β₂-Adrenergic receptor agonists accelerate resolution of pulmonary edema in experimental and clinical studies.


This clinical trial was designed to test the hypothesis that an aerosolized β₂-agonist, albuterol, would improve clinical outcomes in patients with acute lung injury (ALI).


We conducted a multicenter, randomized, placebo-controlled clinical trial in which 282 patients with ALI receiving mechanical ventilation were randomized to receive aerosolized albuterol (5 mg) or saline placebo every 4 hours for up to 10 days. The primary outcome variable for the trial was ventilator-free days.


Ventilator-free days were not significantly different between the albuterol and placebo groups (means of 14.4 and 16.6 d, respectively; 95% confidence interval for the difference, -4.7 to 0.3 d; P = 0.087). Rates of death before hospital discharge were not significantly different between the albuterol and placebo groups (23.0 and 17.7%, respectively; 95%confidence interval for the difference,-4.0 to 14.7%;P = 0.30). In the subset of patients with shock before randomization, the number of ventilator-free days was lower with albuterol, although mortality was not different. Overall, heart rates were significantly higher in the albuterol group by approximately 4 beats/minute in the first 2 days after randomization, but rates of new atrial fibrillation (10% in both groups) and other cardiac dysrhythmias were not significantly different.


These results suggest that aerosolized albuterol does not improve clinical outcomes in patients with ALI. Routine use of β₂-agonist therapy in mechanically ventilated patients with ALI cannot be recommended. Clinical trial registered with (NCT 00434993).

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center